BMRN BioMarin Pharmaceutical Inc.
$55.35▼ -0.72%
Healthcare
Other
After hours
$55.65▲ +0.54%
Oct 27, 5:29 PM ET
Volume 2.45M
Avg Volume (10D) 2.55M
Key Metrics & Fundamentals
Market Cap
$10.71B
P/E Ratio
149.6
Div Yield
0.00%
52W Range
49.26 - 70.98
% vs 50 MA
-9.64%
% vs 200 MA
-5.26%
RSI-14
39.8
MACD Histogram
+0.3300
Beta (1Y vs SPY)
0.36
Free Cash Flow
$133.86M
Gross Rev
$989.71M
Gross Profit
$786.91M
EBITDA
$222.32M
COGS
$202.80M
Operating Exp
$675.94M
Operating Income
$110.97M
EBIT
$110.97M
Pretax Income
$61.38M
Net Income
$44.76M
EPS (Diluted)
0.23
Price & Volume History
Loading chart…
Recent News
BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET
PR Newswire · Oct 26, 2026 9:00 AM ET
Vertex Stock Looks Expensive. Does It Get Cheaper Ahead?
Trefis · Oct 23, 2026 1:29 PM ET
Earnings Preview: Bristol Myers Squibb (BMY) Q3 Earnings Expected to Decline
Zacks · Oct 22, 2026 9:00 AM ET
Why Should You Think About Vertex Differently Now?
Trefis · Oct 20, 2026 8:56 PM ET
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?
Zacks · Oct 19, 2026 9:00 AM ET
UBS Adjusts BioMarin Pharmaceutical Price Target to $88 From $114, Maintains Buy Rating
MT Newswires · Oct 15, 2026 10:33 AM ET
1cBio Received Shareholder Proceeds Upon Closing of BioMarin Pharmaceutical Inc.'s Acquisition of Alesta Therapeutics
PR Newswire · Oct 14, 2026 8:00 AM ET
Is Vertex Stock Worth More Than Its Competitors?
Trefis · Oct 9, 2026 11:36 AM ET
BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting
PR Newswire · Oct 9, 2026 9:05 AM ET
BioMarin Pharmaceutical (BMRN), What Is Behind The Latest Attention?
Simply Wall St. · Oct 8, 2026 2:14 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See BMRN's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.